Vanguard Group Inc. Purchases 97,536 Shares of Moderna, Inc. (NASDAQ:MRNA)

Vanguard Group Inc. lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 40,323,750 shares of the company's stock after acquiring an additional 97,536 shares during the quarter. Vanguard Group Inc. owned approximately 10.48% of Moderna worth $1,676,662,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC grew its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after buying an additional 388 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Moderna Trading Down 3.1 %

Moderna stock traded down $1.00 during mid-day trading on Friday, hitting $31.12. The stock had a trading volume of 5,681,801 shares, compared to its average volume of 6,817,655. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The firm has a market capitalization of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86. The firm's 50 day moving average is $34.72 and its 200 day moving average is $44.38.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. UBS Group reduced their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Leerink Partners lowered their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Bank of America cut their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.